是否用吉非替尼/厄洛替尼进行再治疗：这是酪氨酸激酶抑制剂敏感的进展期肺癌面临的问题。 - Suppr | 超能文献

To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.

作者信息

Costa Daniel B

出版信息

Lung Cancer. 2007 Aug;57(2):251-2. doi: 10.1016/j.lungcan.2007.04.013. Epub 2007 Jun 13.

DOI:10.1016/j.lungcan.2007.04.013

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.是否用吉非替尼/厄洛替尼进行再治疗：这是酪氨酸激酶抑制剂敏感的进展期肺癌面临的问题。

Lung Cancer. 2007 Aug;57(2):251-2. doi: 10.1016/j.lungcan.2007.04.013. Epub 2007 Jun 13.

2

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.表皮生长因子受体（EGFR）的双靶点分子靶向治疗：抗EGFR抗体与酪氨酸激酶抑制剂联合使用。

Cancer Res. 2004 Aug 1;64(15):5355-62. doi: 10.1158/0008-5472.CAN-04-0562.

3

Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.在具有MET扩增的非小细胞肺癌细胞系中，将S-1添加到表皮生长因子受体抑制剂吉非替尼中可克服吉非替尼耐药性。

Clin Cancer Res. 2009 Feb 1;15(3):907-13. doi: 10.1158/1078-0432.CCR-08-2251.

4

Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.晚期非小细胞肺癌中的表皮生长因子受体突变与酪氨酸激酶抑制剂治疗

Technol Eval Cent Assess Program Exec Summ. 2011 Mar;25(6):1-5.

5

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.多种受体酪氨酸激酶抑制剂和哺乳动物雷帕霉素靶蛋白抑制剂的联合应用通过抑制 c-Met 克服了肺癌细胞系对厄洛替尼的耐药性。

Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20.

6

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.酪氨酸激酶抑制剂治疗非小细胞肺癌：寻找有反应的患者。

Expert Rev Respir Med. 2011 Jun;5(3):413-24. doi: 10.1586/ers.11.27.

7

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.非小细胞肺癌患者表皮生长因子受体基因突变及对吉非替尼获得性耐药的分析

Clin Cancer Res. 2006 Oct 1;12(19):5764-9. doi: 10.1158/1078-0432.CCR-06-0714.

8

Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.多发性骨髓瘤中的罕见病例及转移性肺癌中的显著反应：病例4。一名患有晚期、对吉非替尼敏感的非小细胞肺癌老年男性的表皮生长因子受体突变。

J Clin Oncol. 2005 Jan 1;23(1):235-7. doi: 10.1200/JCO.2005.07.169.

9

Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?表皮生长因子受体酪氨酸激酶抑制剂联合化疗：结案了还是仍有待裁决？

J Clin Oncol. 2005 Sep 1;23(25):5856-8. doi: 10.1200/JCO.2005.05.030. Epub 2005 Jul 25.

10

Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.克服第一代表皮生长因子受体酪氨酸激酶抑制剂耐药的分子机制。

Clin Lung Cancer. 2012 Jul;13(4):267-79. doi: 10.1016/j.cllc.2011.09.001. Epub 2011 Dec 9.

引用本文的文献

1

Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.表皮生长因子受体酪氨酸激酶抑制剂治疗后进展的非小细胞肺癌患者的生存预后。

J Korean Med Sci. 2013 Nov;28(11):1595-602. doi: 10.3346/jkms.2013.28.11.1595. Epub 2013 Oct 31.